JP2022162047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022162047A5 JP2022162047A5 JP2022132891A JP2022132891A JP2022162047A5 JP 2022162047 A5 JP2022162047 A5 JP 2022162047A5 JP 2022132891 A JP2022132891 A JP 2022132891A JP 2022132891 A JP2022132891 A JP 2022132891A JP 2022162047 A5 JP2022162047 A5 JP 2022162047A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cell
- cells
- chain
- hla class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024118377A JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625314P | 2012-04-17 | 2012-04-17 | |
| US61/625,314 | 2012-04-17 | ||
| JP2019019289A JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019289A Division JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118377A Division JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022162047A JP2022162047A (ja) | 2022-10-21 |
| JP2022162047A5 true JP2022162047A5 (https=) | 2023-07-03 |
| JP7531925B2 JP7531925B2 (ja) | 2024-08-13 |
Family
ID=48045753
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507006A Pending JP2015514421A (ja) | 2012-04-17 | 2013-03-15 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2022132891A Active JP7531925B2 (ja) | 2012-04-17 | 2022-08-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507006A Pending JP2015514421A (ja) | 2012-04-17 | 2013-03-15 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150056225A1 (https=) |
| EP (2) | EP4253409A3 (https=) |
| JP (4) | JP2015514421A (https=) |
| AU (1) | AU2013249820C1 (https=) |
| CA (2) | CA3085032A1 (https=) |
| DK (1) | DK2838548T5 (https=) |
| ES (1) | ES2959382T3 (https=) |
| FI (1) | FI2838548T3 (https=) |
| HU (1) | HUE063231T2 (https=) |
| PL (1) | PL2838548T3 (https=) |
| PT (1) | PT2838548T (https=) |
| WO (1) | WO2013158292A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| WO2016073955A2 (en) | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| CN107208055B (zh) * | 2015-01-17 | 2021-06-15 | 浙江大学 | 引起免疫原性反应降低的被修饰细胞 |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CN116003593A (zh) | 2016-01-11 | 2023-04-25 | 苏黎世大学 | 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白 |
| US11396536B2 (en) * | 2016-04-27 | 2022-07-26 | University Health Network | Peptide-HLA complexes and methods of producing same |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| CN110637083A (zh) * | 2017-03-20 | 2019-12-31 | 华盛顿大学 | 细胞及其使用和制备方法 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12144825B2 (en) | 2017-06-30 | 2024-11-19 | Cellectis | Cellular immunotherapy for repetitive administration |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| AU2018396083B2 (en) | 2017-12-29 | 2025-09-25 | Cellectis | Method for improving production of CAR T cells |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12331318B2 (en) | 2018-07-13 | 2025-06-17 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
| US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| CN110819592A (zh) * | 2018-08-13 | 2020-02-21 | 赛元生物科技(杭州)有限公司 | 一种通用供体干细胞及其制备方法 |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020231882A2 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US20230071538A1 (en) * | 2020-02-07 | 2023-03-09 | Juntendo Educational Foundation | Cytotoxic t cells derived from human t cell-derived ips cells |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| IL300484A (en) | 2020-08-19 | 2023-04-01 | Astellas Pharma Inc | A human non-naturally occurring modified IgG FC region that specifically binds to a non-naturally occurring modified FC receptor |
| EP4200023A4 (en) | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| CN114276995A (zh) * | 2020-09-28 | 2022-04-05 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ctla-4阻遏分子的多能干细胞及其衍生物 |
| CN114350612A (zh) * | 2020-09-28 | 2022-04-15 | 未来智人再生医学研究院(广州)有限公司 | 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物 |
| CN114457024A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用 |
| CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
| CN114525257A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用 |
| CN114457026A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用 |
| CN114457030A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IgE阻断物的多能干细胞或其衍生物及应用 |
| CN114457028A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd38抗体的多能干细胞及其衍生物与应用 |
| CN114457033A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-6阻断物的多能干细胞衍生物及其应用 |
| CN114525254A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达fgf-21的多能干细胞或其衍生物及应用 |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| CN114517184A (zh) * | 2020-10-30 | 2022-05-20 | 未来智人再生医学研究院(广州)有限公司 | 一种表达adipsin的多能干细胞或其衍生物及应用 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN114645021A (zh) * | 2020-12-21 | 2022-06-21 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用 |
| CN114717192A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114657130A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114657131A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达尿酸氧化酶的多能干细胞或其衍生物 |
| CN114717193A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| CN114657138A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| TW202302839A (zh) | 2021-03-09 | 2023-01-16 | 國立研究開發法人理化學研究所 | 低免疫原性視網膜色素上皮細胞之製造方法 |
| US20240368541A1 (en) | 2021-05-03 | 2024-11-07 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
| WO2022235869A1 (en) | 2021-05-07 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature hepatocytes |
| AU2022299551A1 (en) * | 2021-06-23 | 2024-01-18 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| IL318429A (en) | 2022-08-23 | 2025-03-01 | Astellas Inst For Regenerative Medicine | Photoreceptor rescue cell (PRC) compositions and methods for treating eye disorders |
| CN118207165B (zh) * | 2022-12-07 | 2026-03-20 | 士泽生物医药（苏州）有限公司 | 一种表达stc1的通用型细胞及其制备方法 |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
| WO1992009688A1 (en) * | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| EP0995798A1 (en) * | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| CA2993567C (en) * | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| WO2012145384A1 (en) * | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
-
2013
- 2013-03-15 US US14/391,328 patent/US20150056225A1/en not_active Abandoned
- 2013-03-15 PL PL13714128.9T patent/PL2838548T3/pl unknown
- 2013-03-15 HU HUE13714128A patent/HUE063231T2/hu unknown
- 2013-03-15 EP EP23173587.9A patent/EP4253409A3/en active Pending
- 2013-03-15 WO PCT/US2013/032058 patent/WO2013158292A1/en not_active Ceased
- 2013-03-15 FI FIEP13714128.9T patent/FI2838548T3/fi active
- 2013-03-15 JP JP2015507006A patent/JP2015514421A/ja active Pending
- 2013-03-15 CA CA3085032A patent/CA3085032A1/en active Pending
- 2013-03-15 DK DK13714128.9T patent/DK2838548T5/da active
- 2013-03-15 PT PT137141289T patent/PT2838548T/pt unknown
- 2013-03-15 CA CA2870571A patent/CA2870571C/en active Active
- 2013-03-15 AU AU2013249820A patent/AU2013249820C1/en active Active
- 2013-03-15 ES ES13714128T patent/ES2959382T3/es active Active
- 2013-03-15 EP EP13714128.9A patent/EP2838548B1/en active Active
-
2019
- 2019-02-06 JP JP2019019289A patent/JP7130571B2/ja active Active
- 2019-06-14 US US16/441,889 patent/US20190365876A1/en active Pending
-
2022
- 2022-08-24 JP JP2022132891A patent/JP7531925B2/ja active Active
-
2024
- 2024-07-24 JP JP2024118377A patent/JP2024144548A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022162047A5 (https=) | ||
| JP2024144548A5 (https=) | ||
| JP7531925B2 (ja) | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 | |
| JP7586528B2 (ja) | β２ミクログロブリン欠損細胞 | |
| JP2025010296A5 (https=) | ||
| McAdam et al. | Chimpanzee MHC class IA locus alleles are related to only one of the six families of human A locus alleles. | |
| JP2018174946A5 (https=) | ||
| WO1997026328A1 (en) | Immunotherapy using cytotoxic t lymphocytes (ctl) | |
| Partanen et al. | Low degree of DNA polymorphism in the HLA‐linked lymphotoxin (tumour necrosis factor β) gene | |
| CA2566903A1 (en) | Modified antigen-presenting cells | |
| US12492237B2 (en) | T cell receptors targeting PIK3CA mutations and uses thereof | |
| JPWO2021044377A5 (https=) | ||
| US20240285737A1 (en) | Improved methods of treatment using immunogenic peptides | |
| Sullivan et al. | Molecular analysis of the bare lymphocyte syndrome. | |
| Jacobson et al. | Virus-specific HLA class II-restricted cytotoxic T cells | |
| Voogd | Exploring HLA-E restricted M cobacterium tuberculosis specific T cells as accination targets for Tuberculosis | |
| AU767173B2 (en) | Immunotherapy using cytotoxic T lymphocytes (CTL) | |
| Perarnau et al. | Histocompatibility Antigens | |
| JPWO2021081156A5 (https=) | ||
| Ascher | Gene therapy: Advances and limitations | |
| Shiv Pillai | Cancer Center, Massachusetts General Hospital and Harvard Medical School | |
| Robert | The major histocompatibility complex |